Comparison Overview

Hikma Pharmaceuticals

VS

Novo Nordisk

Hikma Pharmaceuticals

1 New Burlington Place, London, W1S 2HR, GB
Last Update: 2025-12-11
View Profile
Between 750 and 799
http://www.hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,222
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Novo Nordisk

Novo Alle, Bagsværd, undefined, 2880, DK
Last Update: 2025-12-10
Between 800 and 849
https://www.novonordisk.com

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 64,615
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/hikma-pharmaceuticals.jpeg
Hikma Pharmaceuticals
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/novo-nordisk.jpeg
Novo Nordisk
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Hikma Pharmaceuticals
100%
Compliance Rate
0/4 Standards Verified
Novo Nordisk
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Novo Nordisk in 2025.

Incident History — Hikma Pharmaceuticals (X = Date, Y = Severity)

Hikma Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Incident History — Novo Nordisk (X = Date, Y = Severity)

Novo Nordisk cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/hikma-pharmaceuticals.jpeg
Hikma Pharmaceuticals
Incidents

No Incident

https://images.rankiteo.com/companyimages/novo-nordisk.jpeg
Novo Nordisk
Incidents

No Incident

FAQ

Novo Nordisk company demonstrates a stronger AI Cybersecurity Score compared to Hikma Pharmaceuticals company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Novo Nordisk company has disclosed a higher number of cyber incidents compared to Hikma Pharmaceuticals company.

In the current year, Novo Nordisk company and Hikma Pharmaceuticals company have not reported any cyber incidents.

Neither Novo Nordisk company nor Hikma Pharmaceuticals company has reported experiencing a ransomware attack publicly.

Neither Novo Nordisk company nor Hikma Pharmaceuticals company has reported experiencing a data breach publicly.

Neither Novo Nordisk company nor Hikma Pharmaceuticals company has reported experiencing targeted cyberattacks publicly.

Neither Hikma Pharmaceuticals company nor Novo Nordisk company has reported experiencing or disclosing vulnerabilities publicly.

Neither Hikma Pharmaceuticals nor Novo Nordisk holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Hikma Pharmaceuticals company nor Novo Nordisk company has publicly disclosed detailed information about the number of their subsidiaries.

Novo Nordisk company employs more people globally than Hikma Pharmaceuticals company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Hikma Pharmaceuticals nor Novo Nordisk holds SOC 2 Type 1 certification.

Neither Hikma Pharmaceuticals nor Novo Nordisk holds SOC 2 Type 2 certification.

Neither Hikma Pharmaceuticals nor Novo Nordisk holds ISO 27001 certification.

Neither Hikma Pharmaceuticals nor Novo Nordisk holds PCI DSS certification.

Neither Hikma Pharmaceuticals nor Novo Nordisk holds HIPAA certification.

Neither Hikma Pharmaceuticals nor Novo Nordisk holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
References
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
References
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N
References